79 related articles for article (PubMed ID: 38222041)
1. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.
Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V
TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041
[No Abstract] [Full Text] [Related]
2. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
Pipe SW; Collins P; Dhalluin C; Kenet G; Schmitt C; Buri M; Jiménez-Yuste V; Peyvandi F; Young G; Oldenburg J; Mancuso ME; Kavakli K; Kiialainen A; Deb S; Niggli M; Chang T; Lehle M; Fijnvandraat K
Blood; 2024 Apr; 143(14):1355-1364. PubMed ID: 38127586
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Mahlangu J; Jiménez-Yuste V; Ventriglia G; Niggli M; Barlera S; Hermans C; Lehle M; Chowdary P; Jew L; Windyga J; Frenzel L; Schmitt C; Castaman G; Pipe SW
Res Pract Thromb Haemost; 2024 Feb; 8(2):102364. PubMed ID: 38559572
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence.
Linari S; Castaman G
Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043
[TBL] [Abstract][Full Text] [Related]
5. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study.
Nogami K; Fujii T; Sawada A; Nagao A; Nagae C; Nojima M; Suzuki N; Nosaka D; Shimura T; Sugao Y; Amano K
Int J Hematol; 2024 Jan; 119(1):14-23. PubMed ID: 38100026
[TBL] [Abstract][Full Text] [Related]
6. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.
Warren BB; Chan A; Manco-Johnson M; Branchford BR; Buckner TW; Moyer G; Gibson E; Thornhill D; Wang M; Ng CJ
Res Pract Thromb Haemost; 2021 Jul; 5(5):e12571. PubMed ID: 34377887
[TBL] [Abstract][Full Text] [Related]
7. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice.
Shimizu K; Nakajima Y; Takami E; Nakano H; Nogami K
Thromb Haemost; 2024 May; ():. PubMed ID: 38677278
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.
Jiménez-Yuste V; Oldenburg J; Tzeng E; Lim E; Sanabria F; Mahlangu J
Res Pract Thromb Haemost; 2024 Mar; 8(3):102405. PubMed ID: 38783987
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review.
Young G; Pipe SW; Kenet G; Oldenburg J; Safavi M; Czirok T; Nissen F; Mahlangu J
Res Pract Thromb Haemost; 2024 May; 8(4):102415. PubMed ID: 38812987
[TBL] [Abstract][Full Text] [Related]
10. Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.
Gupta N; Dutta A; Ahmed B; Ross CR; S C; Dolan G; John MJ; Radhakrishnan N; Aggarwal S; Seth T; Kaul V; Shah V
Cureus; 2024 Apr; 16(4):e58941. PubMed ID: 38725780
[TBL] [Abstract][Full Text] [Related]
11. Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.
Jiménez-Yuste V; Álvarez-Román MT; Berrueco R; Bonanad S; Calvo-Villas JM; González-González R; Porras JRG; Núñez-Vázquez RJ; Rodríguez-López M
TH Open; 2024 Apr; 8(2):e194-e201. PubMed ID: 38633730
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab as first-line therapy in acquired hemophilia A.
Iarossi M; Hermans C
Res Pract Thromb Haemost; 2024 May; 8(4):102438. PubMed ID: 38953052
[TBL] [Abstract][Full Text] [Related]
13. Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.
Xu Y; Wang Y; Wu R; Zheng C; Zhang L; Xu W; Feng X; Wang H; Cao X; He L; Xue T; Jin M; Xie B; Ling J; Sun L; Su R; Cheng H; Fang Y; Poon MC; Liu W; Zhang L; Xue F; Yang R
Haemophilia; 2024 Jun; ():. PubMed ID: 38853005
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy.
Arshad S; Singh A; Awasthi NP; Kumari S; Husain N
Ther Adv Hematol; 2018 Aug; 9(8):213-226. PubMed ID: 30181842
[TBL] [Abstract][Full Text] [Related]
15. Disease Burden, Clinical Outcomes, and Quality of Life in People with Hemophilia A without Inhibitors in Europe: Analyses from CHESS II/CHESS PAEDs.
Chowdary P; Ofori-Asenso R; Nissen F; Grazzi EF; Aizenas M; Moreno K; Burke T; Nolan B; O'Hara J; Khair K
TH Open; 2024 Apr; 8(2):e181-e193. PubMed ID: 38628421
[No Abstract] [Full Text] [Related]
16. Cholecystectomy in a man with hemophilia A and inhibitor on emicizumab prophylaxis: A case report.
Giacometto PC; Bavaresco MT; Alvares-Teodoro J; Camelo RM
Hematol Transfus Cell Ther; 2024; 46(2):201-204. PubMed ID: 36481198
[No Abstract] [Full Text] [Related]
17. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.
Lemos F; Petraccia C; Fraga ML; Casuriaga AL; Lutz S; Gómez R; Giachetto G; Boggia B
Haemophilia; 2024 Apr; ():. PubMed ID: 38684449
[No Abstract] [Full Text] [Related]
18. A challenging management of hemophilia B patient with inhibitors undergoing major orthopedic surgeries in a resource-constrained country.
Matrane W; Nsiri A; Rafai M; Midmani F; Boughaza N; Cherkaoui S; Qachouh M; Khoubila N
Clin Case Rep; 2020 Dec; 8(12):2995-2999. PubMed ID: 33363866
[TBL] [Abstract][Full Text] [Related]
19. Correction: Expert Opinions on the Management of Hemophilia A in India: The Role of Emicizumab.
Gupta N; Dutta A; Ahmed B; Ross CR; S C; Dolan G; John MJ; Radhakrishnan N; Aggarwal S; Seth T; Kaul V; Shah V
Cureus; 2024 May; 16(5):c172. PubMed ID: 38726357
[TBL] [Abstract][Full Text] [Related]
20. Major Orthopaedic Surgery in Persons with Haemophilia A with and without Inhibitors Treated by Emicizumab: A Mid-Term, Large, and Successful Series at a Single Center.
Carulli C; Daniele G; Linari S; Pieri L; Littera M; Mazzetti M; Tamburini C; Prisco D; Castaman G
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731175
[No Abstract] [Full Text] [Related]
[Next] [New Search]
